The U.S. pharmacy benefit manager owned by Cigna Corp said the offer
included thousands of generic drugs, which would be priced at $25
and branded medications priced at $75.
Express said the offer, which is temporary, includes drugs for
asthma, diabetes drug, glaucoma, heart disease, migraine,
reproductive health, seizures and thyroid conditions. The discount
level will vary because of the wide range in retail prices for
generic and branded drugs in the United States.
Trulicity, a diabetes treatment from Eli Lilly and Co included in
the scheme, is listed at $694 on the GoodRx pharmacy website, where
Vyzulta, an eye drop made by Bausch Health Cos, costs around $220.
Meanwhile, Airduo, an asthma inhaler made by Teva Pharmaceuticals,
costs about $50.
The White House on Tuesday estimated the unemployment rate in April
was 16% to 20%, representing more than 20 million jobs lost, as
social distancing and shelter-in-place orders aimed at curbing the
coronavirus shut all but essential services.
More than half of Americans have health insurance through their
employers, while others buy individual health insurance plans, some
of which include government income-based subsidies.
[to top of second column] |
Some get Medicaid benefits for the poor or have healthcare paid for by the
Medicare program for disabled people and those aged 65 or older, while others
have no insurance at all.
Express said that more than 40 branded medications in its program would come
from drugmakers including AstraZeneca PLC, Bayer AG, Eli Lilly and Co , Merck &
Co, Pfizer Inc, Sanofi SA and UCB SA.
Discounts in the scheme, dubbed ParachuteRx, originate partly from manufacturers
as well as pharmacies, Express said, adding that the drugs are available by mail
and at most pharmacies including Walgreens Boots Alliance, CVS Health Corp and
Rite Aid Corp.
(Reporting by Caroline Humer; Editing by Alexander Smith)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |